Time Required to Address Scientific Questions Generates an Information Dilemma
One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.
Objectively Accurate Interpretation of Clinical Trials Results Poses a Challenge
Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.
Challenges Arise as Public Health and Scientific Communication Enters Uncharted Territory
It is difficult to dispute that these are troubling times for government officials and public health agencies.
Patient Perspective Should Be Part of Assessing Value in Cancer Care
Costs associated with anticancer therapeutics continue to rise, although it also is recognized that the overall effectiveness of therapy has improved.
Dr. Markman on Privacy and Consent in Clinical Cancer Trials and Beyond
Maurie Markman, MD, discusses how privacy and consent in clinical cancer trials have improved over the years.
Pandemic Heightens Stress of Cancer Diagnosis
The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.
Innovations in the Management of Advanced Cervical Cancer: Focus on Multidisciplinary Care
The management of carcinoma of the cervix represents a remarkable dichotomy.
The Dilemma of New Evidence: When to Shift Gears
When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?
Dr. Markman on Timing of BSO in Patients With Ovarian Cancer
Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512